Tschoepe, Carsten and Birner, Christoph and Bohm, Michael and Bruder, Oliver and Frantz, Stefan and Luchner, Andreas and Maier, Lars and Stoerk, Stefan and Kherad, Behrouz and Laufs, Ulrich (2018) Heart failure with preserved ejection fraction: current management and future strategies. CLINICAL RESEARCH IN CARDIOLOGY, 107 (1). pp. 1-19. ISSN 1861-0684, 1861-0692
Full text not available from this repository. (Request a copy)Abstract
About 50% of all patients suffering from heart failure (HF) exhibit a reduced ejection fraction (EF <= 40%), termed HFrEF. The others may be classified into HF with midrange EF (HFmrEF 40-50%) or preserved ejection fraction (HFpEF, EF >= 50%). Presentation and pathophysiology of HFpEF is heterogeneous and its management remains a challenge since evidence of therapeutic benefits on outcome is scarce. Up to now, there are no therapies improving survival in patients with HFpEF. Thus, the treatment targets symptom relief, quality of life and reduction of cardiac decompensations by controlling fluid retention and managing risk factors and comorbidities. As such, reninangiotensin-aldosterone inhibitors, diuretics, calcium channel blockers (CBB) and beta-blockers, diet and exercise recommendations are still important in HFpEF, although these interventions are not proven to reduce mortality in large randomized controlled trials. Recently, numerous new treatment targets have been identified, which are further investigated in studies using, e.g. soluble guanylate cyclase stimulators, inorganic nitrates, the angiotensin receptor neprilysin inhibitor LCZ 696, and SGLT2 inhibitors. In addition, several devices such as the CardioMEMS, interatrial septal devices (IASD), cardiac contractility modulation (CCM), renal denervation, and baroreflex activation therapy (BAT) were investigated in different forms of HFpEF populations and some of them have the potency to offer new hopes for patients suffering from HFpEF. On the basic research field side, lot of new disease-modifying strategies are under development including anti-inflammatory drugs, mitochondrial-targeted antioxidants, new anti-fibrotic and microRNA-guided interventions are under investigation and showed already promising results. This review addresses available data of current best clinical practice and management approaches based on expert experiences and summarizes novel approaches towards HFpEF
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | LEFT-VENTRICULAR FUNCTION; GUANYLATE-CYCLASE STIMULATOR; IMPROVES DIASTOLIC FUNCTION; QUALITY-OF-LIFE; EXERCISE CAPACITY; CARDIAC FIBROSIS; RATE REDUCTION; BETA-BLOCKERS; PULMONARY-HYPERTENSION; FERRIC CARBOXYMALTOSE; Heart failure; HFpEF |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin II |
| Depositing User: | Petra Gürster |
| Date Deposited: | 23 Jun 2020 12:35 |
| Last Modified: | 23 Jun 2020 12:35 |
| URI: | https://pred.uni-regensburg.de/id/eprint/15470 |
Actions (login required)
 |
View Item |
